EOS imaging Announces First Installation in Asia

PARIS--(BUSINESS WIRE)--EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announces the first installation of its EOS® system in Asia, at Singapore’s National University Hospital (NUH).

“We are very pleased to be able to allow our patients to benefit from EOS technology, both within the framework of routine clinical screenings and as part of the substantial clinical research work we carry out in our establishment.”

A member of the National University Health System, the internationally-recognized NUH is a leading center in a number of medical specialties, including orthopedic surgery, and features the region’s most innovative medical technologies. In 2004, NUH became the first Singapore hospital to receive Joint Commission International (JCI) accreditation, an international stamp of excellence for clinical practices.

Professor Hee Kit Wong, Head of the University Spine Centre and Chair of the University Orthopedics Hand & Reconstructive Microsurgery Cluster, NUH, welcomes the installation of an EOS, stating, “We are very pleased to be able to allow our patients to benefit from EOS technology, both within the framework of routine clinical screenings and as part of the substantial clinical research work we carry out in our establishment.”

Marie Meynadier, CEO of EOS imaging, says, “The installation of EOS equipment at NUH represents a milestone in our development in Asia, and validates the appeal of our technology for state-of-the-art medical centers. We will build on the success of this first installation in such a prestigious and well-known institution to deploy our technology throughout Southeast Asia, a geographical region with substantial potential.”

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit www.eos‐imaging.com.

About EOS imaging:

The EOS imaging group designs, develops and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Group has obtained authorization to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EC). Thanks to an installed base of 48 sites and more than 250,000 imaging sessions, EOS® benefits from worldwide recognition and established credibility within the medical community. The Group currently employs 59 people, including an R&D team of 21 engineers and recorded consolidated revenue of €6.94 million in 2011. The Group's head office is based in Paris, with a subsidiary in the United States at Cambridge (Massachusetts), in Montreal (Canada) and in Germany.

EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Next press release: revenue for the 3^rd quarter of 2012 on 15 November 2012 (after market).